热门资讯> 正文
Nektar上涨5%，陪审团判给9000万美元加上礼来审判的利息
2026-09-25 19:26
- 礼来(LLY) 0
- 内克塔治疗(NKTR) 0
- 诺和诺德(NVO) 0
- Nektar Therapeutics (NKTR) on Friday said that a U.S. jury found Eli Lilly (LLY) liable for breaching an implied covenant of good faith and fair dealing in a dispute over their former collaboration on rezpegaldesleukin, awarding Nektar $90M in damages plus interest.
- Nektar's shares, up 40% this year, rose nearly 5% in premarket trading following the filing.
- The jury’s verdict remains subject to post-trial proceedings, and any resulting judgment may be subject to appeal.
- In August 2023, Nektar Therapeutics sued Eli Lilly in a California federal court, alleging breaches of contract and good faith related to their former rezpegaldesleukin collaboration.
More on Nektar Therapeutics, Eli Lilly
- Eli Lilly Vs. Novo Nordisk: Temporarily Cheap Or Correctly Cheap?
- Eli Lilly and Company (LLY) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
- Eli Lilly Stock Is Not Done Growing Yet, But It's Due For Compression (Rating Downgrade)
- FDA commissioner nominee Overton rebuffs questions about Trump medical claims
- Lilly wins FDA nod for once-weekly insulin product, Onswik
推荐文章
一图看懂 | 潘渡SOL ETF开启申购！紧密追踪Solana价格表现
Anthropic营收增长面临挑战，微软和Meta据悉限制员工使用Claude模型
30年期收益率本月将破6%？经济韧性与通胀压力推高利率 美债抛售潮进一步加剧
美股异动 | Cerebras大涨近9%，与OpenAI正展开“深度合作”；SPCX涨近4%，微软涨近2%
美股前瞻 | 美联储10月加息概率已不足25%；台积电盘前涨2%开盘将创新高；高通与华为达成重磅专利协议
特朗普成立“超级智能工作组”：情报总监牵头，协调联邦政府AI事务
渣打2026年第四季市场展望！恒指12个月目标26000-27000点，核心配置中国内地、香港股市
美债收益率居高不下！高借贷成本持续冲击美国经济 AI投资热潮与实体经济表现分化加剧
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
